2020 ASCO Virtual Scientific Meeting*

May 29-31, 2020; Online at meetings.asco.org/am
Review slidesets and expert analyses of key data from the 2020 Clinical Oncology Virtual Scientific Meeting!

Hematologic Malignancies

Capsule Summary Slidesets

Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.

Released: June 1, 2020

Enasidenib plus azacitidine showed significantly improved response rates compared with azacitidine alone in patients with mIDH2 newly diagnosed acute myeloid leukemia.

Released: June 4, 2020

Combined with azacytidine, the anti-CD47 antibody magrolimab was well tolerated and associated with promising activity in untreated patients with MDS and AML.

Released: June 5, 2020

AMG 330, a CD33- and CD3-targeted bispecific T-cell engager appears safe and tolerable in dose-escalation study in patients with R/R AML.

Released: June 2, 2020

In these additional analyses of CC-486 for patients with AML CC-486 was found to preserve health-related quality of life, be well tolerated and effective in older patients, and with dosing escalation improve response in patients with early relapse.

Released: June 5, 2020

Pembrolizumab significantly improved PFS in patients with relapsed/refractory cHL vs brentuximab vedotin, including those ineligible for ASCT, with primary refractory disease, and who were brentuximab vedotin naive.

Released: June 9, 2020

Zanubrutinib demonstrated a nonsignificant improvement in response rate and lower rates of several adverse events vs ibrutinib in patients with Waldenström macroglobulinemia.

Released: June 9, 2020

Epcoritamab was associated with rapid, deep responses and low-grade CRS in heavily pretreated patients with R/R NHL.

Released: June 5, 2020

Standard-risk younger patients with R/R cHL achieved high CMR with nivolumab plus brentuximab vedotin as first-line salvage therapy.

Released: June 3, 2020

Extended follow-up data from multiple studies confirm significant efficacy and tolerability of acalabrutinib in CLL and other B-cell malignancies.

Released: June 3, 2020

Weekly triplet regimen SVd significantly improved PFS compared with twice weekly Vd in multiple myeloma patients with 1-3 previous therapies

Released: June 1, 2020

Belantamab mafodotin plus bortezomib/dexamethasone showed promising efficacy in heavily pretreated patients with RR myeloma.

Released: June 5, 2020

Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.

Released: June 4, 2020

BCMA-directed CAR T-cell therapy with orva-cel demonstrated robust activity in a dose-finding phase I study of heavily pretreated patients with multiple myeloma.

Released: June 2, 2020

For newly diagnosed patients with multiple myeloma, adding RVD consolidation or a second ASCT to initial ASCT plus lenalidomide maintenance did not improve PFS or OS at 6 years for those with no progression at 38 months.

Released: June 10, 2020

Addition of elotuzumab to RVd induction and maintenance therapy did not improve outcomes in patients with high-risk multiple myeloma

Released: June 1, 2020

Venetoclax plus bortezomib/dexamethasone was selectively associated with favorable survival outcomes in patients with R/R myeloma and the t(11;14) cytogenetic marker in this updated study analysis.

Released: June 2, 2020

In standard- or intermediate-risk patients with newly diagnosed MM who were not intended for early ASCT, KRd did not improve PFS compared with VRd

Released: June 9, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?